Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
OncLive’s April Roundup of Key FDA Decisions in Oncology
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment
Action is Key to Continue to Break Down Barriers for Equitable Cancer Care
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer